logo
Plus   Neg
Share
Email

FDA Approves Teva's Generic EpiPen, Shares Up 6%

The U.S. Food and Drug Administration Thursday approved the first generic version of Mylan's EpiPen for the emergency treatment of allergic reactions. Teva Pharmaceuticals gained the US regulator's approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths.

Shares of Teva gained 6 percent following the news and is currently trading at $23.91.

"Today's approval of the first generic version of the most-widely prescribed epinephrine auto-injector in the U.S. is part of our longstanding commitment to advance access to lower cost, safe and effective generic alternatives once patents and other exclusivities no longer prevent approval," said FDA Commissioner Scott Gottlieb, M.D.

"This approval means patients living with severe allergies who require constant access to life-saving epinephrine should have a lower-cost option, as well as another approved product to help protect against potential drug shortages.

In 2016, FDA had rejected Teva's application for a generic EpiPen.

The EpiPen is intended to automatically inject a dose of epinephrine into a person's thigh to stop an allergic reaction. The FDA has approved several epinephrine auto-injector products under new drug applications to treat anaphylaxis, including EpiPen, Adrenaclick and Auvi-Q.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home Meridian has announced recall of about 520 Copeland Corner Curio cabinets due to a risk of tip-over. According to Home Meridian, the recalled curio cabinets are unstable if they are not anchored to the wall, which poses a significant risk of tip-over and entrapment resulting in death or injuries... Hershey decided to replace its green and black label of Take 5 bar with new, attractive packaging. It will be marketed as Reese's peanut butter with a catchy orange wrapper. However, the ingredients will not change. Harley-Davidson, in collaboration with Qianjiang Motorcycle co., plan to launch smaller engine capacity bikes of 338 CC in China by 2020. This is part of the company's strategic move to expand its bike production to Asian countries.
Follow RTT